CY1118157T1 - Εκλεκτικοι αναστολεις γλυκοσιδασης και χρησεις αυτων - Google Patents
Εκλεκτικοι αναστολεις γλυκοσιδασης και χρησεις αυτωνInfo
- Publication number
- CY1118157T1 CY1118157T1 CY20161100886T CY161100886T CY1118157T1 CY 1118157 T1 CY1118157 T1 CY 1118157T1 CY 20161100886 T CY20161100886 T CY 20161100886T CY 161100886 T CY161100886 T CY 161100886T CY 1118157 T1 CY1118157 T1 CY 1118157T1
- Authority
- CY
- Cyprus
- Prior art keywords
- compounds
- inspectors
- extensive
- glucose residues
- prodrugs
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 abstract 4
- 230000007812 deficiency Effects 0.000 abstract 2
- 239000000651 prodrug Substances 0.000 abstract 2
- 229940002612 prodrug Drugs 0.000 abstract 2
- 108010031186 Glycoside Hydrolases Proteins 0.000 abstract 1
- 102000005744 Glycoside Hydrolases Human genes 0.000 abstract 1
- OVRNDRQMDRJTHS-UHFFFAOYSA-N N-acelyl-D-glucosamine Natural products CC(=O)NC1C(O)OC(CO)C(O)C1O OVRNDRQMDRJTHS-UHFFFAOYSA-N 0.000 abstract 1
- OVRNDRQMDRJTHS-RTRLPJTCSA-N N-acetyl-D-glucosamine Chemical compound CC(=O)N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-RTRLPJTCSA-N 0.000 abstract 1
- MBLBDJOUHNCFQT-LXGUWJNJSA-N N-acetylglucosamine Natural products CC(=O)N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO MBLBDJOUHNCFQT-LXGUWJNJSA-N 0.000 abstract 1
- 102100030122 Protein O-GlcNAcase Human genes 0.000 abstract 1
- 238000009825 accumulation Methods 0.000 abstract 1
- 230000035508 accumulation Effects 0.000 abstract 1
- 208000037765 diseases and disorders Diseases 0.000 abstract 1
- 108010045982 hexosaminidase C Proteins 0.000 abstract 1
- 230000005764 inhibitory process Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 230000002018 overexpression Effects 0.000 abstract 1
- 230000035699 permeability Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H9/00—Compounds containing a hetero ring sharing at least two hetero atoms with a saccharide radical
- C07H9/06—Compounds containing a hetero ring sharing at least two hetero atoms with a saccharide radical the hetero ring containing nitrogen as ring hetero atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/429—Thiazoles condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H9/00—Compounds containing a hetero ring sharing at least two hetero atoms with a saccharide radical
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/914—Hydrolases (3)
- G01N2333/924—Hydrolases (3) acting on glycosyl compounds (3.2)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/20—Screening for compounds of potential therapeutic value cell-free systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Pulmonology (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- General Engineering & Computer Science (AREA)
- Physical Education & Sports Medicine (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Dermatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Urology & Nephrology (AREA)
- Cardiology (AREA)
- Rheumatology (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201061426773P | 2010-12-23 | 2010-12-23 | |
| PCT/CN2011/074569 WO2012159262A1 (en) | 2011-05-24 | 2011-05-24 | Selective glycosidase inhibitors and uses thereof |
| US201161507684P | 2011-07-14 | 2011-07-14 | |
| PCT/CA2011/001397 WO2012083435A1 (en) | 2010-12-23 | 2011-12-21 | Selective glycosidase inhibitors and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1118157T1 true CY1118157T1 (el) | 2017-06-28 |
Family
ID=46312954
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20161100886T CY1118157T1 (el) | 2010-12-23 | 2016-09-07 | Εκλεκτικοι αναστολεις γλυκοσιδασης και χρησεις αυτων |
Country Status (26)
| Country | Link |
|---|---|
| US (2) | US9243020B2 (enExample) |
| EP (1) | EP2655388B1 (enExample) |
| JP (2) | JP5861194B2 (enExample) |
| KR (1) | KR101979036B1 (enExample) |
| CN (1) | CN103339138B (enExample) |
| AR (1) | AR085004A1 (enExample) |
| AU (1) | AU2011349021B2 (enExample) |
| BR (1) | BR112013016179A2 (enExample) |
| CA (1) | CA2822493C (enExample) |
| CO (1) | CO6821931A2 (enExample) |
| CY (1) | CY1118157T1 (enExample) |
| DK (1) | DK2655388T3 (enExample) |
| ES (1) | ES2589164T3 (enExample) |
| HR (1) | HRP20161079T1 (enExample) |
| HU (1) | HUE030624T2 (enExample) |
| IL (1) | IL227055A (enExample) |
| LT (1) | LT2655388T (enExample) |
| MX (1) | MX343822B (enExample) |
| MY (1) | MY165728A (enExample) |
| NZ (1) | NZ612703A (enExample) |
| PL (1) | PL2655388T3 (enExample) |
| PT (1) | PT2655388T (enExample) |
| RU (1) | RU2609210C2 (enExample) |
| TW (1) | TWI572609B (enExample) |
| WO (1) | WO2012083435A1 (enExample) |
| ZA (1) | ZA201305531B (enExample) |
Families Citing this family (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2006220187B2 (en) * | 2005-03-01 | 2012-11-08 | Simon Fraser University | Selective glycosidase inhibitors, methods of making inhibitors, and uses thereof |
| EP2057171A4 (en) | 2006-08-31 | 2010-04-21 | Univ Fraser Simon | SELECTIVE GLYCOSIDASE INHIBITORS AND APPLICATIONS THEREOF |
| JP5687194B2 (ja) * | 2008-08-01 | 2015-03-18 | サイモン フレイザー ユニバーシティ | 選択的グリコシダーゼインヒビターおよびその使用 |
| US9120781B2 (en) | 2010-05-11 | 2015-09-01 | Simon Fraser University | Selective glycosidase inhibitors and uses thereof |
| WO2012061927A1 (en) | 2010-11-08 | 2012-05-18 | Alectos Therapeutics, Inc. | Selective glycosidase inhibitors and uses thereof |
| BR112013016179A2 (pt) * | 2010-12-23 | 2018-07-10 | Alectos Therapeutics Inc | inibidores seletivos da glicosidase e usos dos mesmos. |
| WO2012126091A1 (en) | 2011-03-24 | 2012-09-27 | Alectos Therapeutics Inc. | Selective glycosidase inhibitors and uses thereof |
| US9718854B2 (en) | 2011-03-31 | 2017-08-01 | Alectos Therapeutics Inc. | Selective glycosidase inhibitors and uses thereof |
| MX364602B (es) * | 2011-06-27 | 2019-05-02 | Alectos Therapeutics Inc | Inhibidores selectivos de glicosidasa y usos de los mismos. |
| WO2013000085A1 (en) | 2011-06-27 | 2013-01-03 | Alectos Therapeutics Inc. | Selective glycosidase inhibitors and uses thereof |
| WO2013000086A1 (en) | 2011-06-27 | 2013-01-03 | Alectos Therapeutics Inc. | Selective glycosidase inhibitors and uses thereof |
| US8884023B2 (en) | 2011-08-25 | 2014-11-11 | Merck Patent Gmbh | Pyrano [3,2-D][1,3]thiazole as glycosidase inhibitors |
| EP2890675A4 (en) | 2012-08-31 | 2016-01-13 | Alectos Therapeutics Inc | GLYCOSIDASE INHIBITORS AND USES THEREOF |
| EP2890676B1 (en) | 2012-08-31 | 2018-12-05 | Alectos Therapeutics Inc. | Glycosidase inhibitors and uses thereof |
| EP2914604A4 (en) * | 2012-10-31 | 2016-07-20 | Alectos Therapeutics Inc | GLYCOSIDASE INHIBITORS AND USES THEREOF |
| WO2014100934A1 (en) * | 2012-12-24 | 2014-07-03 | Merck Sharp & Dohme Corp. | Glycosidase inhibitors and uses thereof |
| MX381417B (es) | 2014-08-28 | 2025-03-12 | Asceneuron Sa | Inhibidores de glucosidasa. |
| KR101777164B1 (ko) | 2015-07-20 | 2017-09-11 | 순천향대학교 산학협력단 | O-GlcNAc 트랜스퍼레즈 억제제용 UDP-GlcNAc의 C1-포스포네이트 유도체 |
| AR106977A1 (es) * | 2015-12-14 | 2018-03-07 | Amicus Therapeutics Inc | Compuestos para el tratamiento de la enfermedad de alzheimer y/o la angiopatía amiloide cerebral |
| JP6971999B2 (ja) | 2016-02-25 | 2021-11-24 | エースニューロン・ソシエテ・アノニム | ピペラジン誘導体の酸付加塩 |
| CN108884077A (zh) | 2016-02-25 | 2018-11-23 | 阿森纽荣股份公司 | 糖苷酶抑制剂 |
| JP2019506430A (ja) | 2016-02-25 | 2019-03-07 | エースニューロン・ソシエテ・アノニム | グリコシダーゼ阻害剤 |
| US11261183B2 (en) | 2016-02-25 | 2022-03-01 | Asceneuron Sa | Sulfoximine glycosidase inhibitors |
| US11213525B2 (en) | 2017-08-24 | 2022-01-04 | Asceneuron Sa | Linear glycosidase inhibitors |
| CN107814773B (zh) * | 2017-11-13 | 2020-05-22 | 西安交通大学 | 含有喹唑啉酮的二芳基脲类化合物及其制备方法和应用 |
| US20210115040A1 (en) * | 2018-06-20 | 2021-04-22 | Janssen Pharmaceutica Nv | Oga inhibitor compounds |
| WO2020039029A1 (en) | 2018-08-22 | 2020-02-27 | Asceneuron S. A. | Spiro compounds as glycosidase inhibitors |
| US11795165B2 (en) | 2018-08-22 | 2023-10-24 | Asceneuron Sa | Tetrahydro-benzoazepine glycosidase inhibitors |
| US12016852B2 (en) | 2018-08-22 | 2024-06-25 | Asceneuron Sa | Pyrrolidine glycosidase inhibitors |
| CA3110032A1 (en) | 2018-08-22 | 2020-02-27 | Asceneuron S.A. | Succinate and fumarate acid addition salts of piperazine derivatives |
| US12612380B2 (en) * | 2019-05-10 | 2026-04-28 | Alectos Therapeutics 1Nc | Non-lysosomal glucosylceramidase inhibitors and uses thereof |
| CN111956656B (zh) * | 2020-08-28 | 2021-10-15 | 河北大学 | Oga抑制剂在制备抗肿瘤药物中的应用 |
| WO2024083820A1 (en) | 2022-10-18 | 2024-04-25 | Institut National de la Santé et de la Recherche Médicale | Method and composition for determining the level of o-glcnacylation in horses |
| CN117679413A (zh) * | 2023-12-06 | 2024-03-12 | 苏州大学 | 一种心梗药物及其应用 |
Family Cites Families (78)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS423500Y1 (enExample) | 1964-02-29 | 1967-03-01 | ||
| DE2632243C3 (de) | 1976-07-17 | 1979-08-30 | Heidelberger Druckmaschinen Ag, 6900 Heidelberg | Auf variable Bogenlängen einstellbare Umführtrommel für Druckmaschinen |
| DE3620645A1 (de) | 1985-12-20 | 1987-07-02 | Bayer Ag | 3-amino-4,5-dihydroxypiperidine, verfahren zu ihrer herstellung und ihre verwendung |
| DE3780344T2 (de) | 1986-03-27 | 1993-01-28 | Sumitomo Pharma | Beta-lactam-verbindungen und deren herstellung. |
| SU1441749A1 (ru) * | 1987-03-16 | 1996-01-10 | Институт Тонкой Органической Химии Им.А.Л.Мнджояна | 2-АМИНО-5,5-ДИМЕТИЛ-4,5-ДИГИДРО-7Н-ПИРАНО [4,3-d] ТИАЗОЛ, ОБЛАДАЮЩИЙ ТРАНКВИЛИЗИРУЮЩЕЙ АКТИВНОСТЬЮ |
| JPS6461459A (en) | 1987-08-28 | 1989-03-08 | Nippon Shinyaku Co Ltd | Moranoline derivative |
| JPH01180894A (ja) | 1988-01-07 | 1989-07-18 | Wako Pure Chem Ind Ltd | アミノ糖誘導体の新規な製造法 |
| GB8900719D0 (en) | 1989-01-13 | 1989-03-08 | Nycomed As | Compounds |
| US5079254A (en) | 1990-06-04 | 1992-01-07 | Merrell Dow Pharmaceuticals Inc. | Derivatives of 6-aminooctahydroindolizinetriol |
| WO1992003415A1 (en) | 1990-08-14 | 1992-03-05 | Nova Pharmaceutical Corporation | Protein kinase c modulators |
| US5276120A (en) | 1991-05-30 | 1994-01-04 | The Scripps Research Institute | Process for forming omega-deuxy-azasugars |
| US6291657B1 (en) | 1993-05-13 | 2001-09-18 | Monsanto Company | Deoxygalactonojirimycin derivatives |
| US5451679A (en) | 1994-03-08 | 1995-09-19 | G. D. Searle & Co. | 2-chloro and 2-bromo derivatives of 1,5-iminosugars |
| JPH07316178A (ja) | 1994-05-25 | 1995-12-05 | Sankyo Co Ltd | 糖アミノオキサゾリン類 |
| CN1131672A (zh) | 1994-11-22 | 1996-09-25 | 生化学工业株式会社 | 氨基环戊烷衍生物 |
| CA2235415A1 (en) | 1995-09-08 | 1997-03-13 | Novo Nordisk A/S | 2-alkylpyrrolidines |
| CZ120398A3 (cs) | 1995-09-08 | 1998-12-16 | Novo Nordisk A/S | Použití 2-alkylpyrrolidinových derivátů pro přípravu léčiva pro léčbu diabetu, 2-alkylpyrrolidiné deriváty |
| JPH09132585A (ja) | 1995-11-10 | 1997-05-20 | Shin Etsu Chem Co Ltd | 新規アミノ糖及びキトオリゴ糖又はその類似オリゴ糖の製造方法 |
| US6407103B2 (en) | 1998-04-21 | 2002-06-18 | Bristol-Myers Squibb Pharma Company | Indeno [1,2-c] pyrazol-4-ones and their uses |
| JPH11349541A (ja) | 1998-06-08 | 1999-12-21 | Sankyo Co Ltd | アロサミゾリン誘導体の新規な中間体 |
| GB9818732D0 (en) | 1998-08-27 | 1998-10-21 | Univ Portsmouth | Collection of compounds |
| US6774140B1 (en) | 1999-05-11 | 2004-08-10 | The Scripps Research Institute | Iminocyclitol inhibitors of hexoaminidase and glycosidase |
| WO2000068194A1 (en) | 1999-05-11 | 2000-11-16 | The Scripps Research Institute | Iminocyclitol inhibitors of hexoaminidase and glycosidase |
| FR2817472B1 (fr) | 2000-12-06 | 2003-01-03 | Oreal | Composition de teinture d'oxydation a base de 1-(4-aminophenyl)pyrrolidines substituees au moins en position 2 et 3 et procede de teinture de mise en oeuvre |
| EP1371733B1 (en) | 2001-03-14 | 2011-05-11 | Denki Kagaku Kogyo Kabushiki Kaisha | Process for producing hyaluronic acid or its derivative |
| JP4233262B2 (ja) | 2001-03-14 | 2009-03-04 | 生化学工業株式会社 | カルバ糖アミン誘導体及びそれを用いるグリコシダーゼ阻害剤 |
| WO2003008379A1 (en) | 2001-06-08 | 2003-01-30 | Mitsubishi Chemical Corporation | Azasugar compounds |
| JP4866515B2 (ja) | 2001-07-02 | 2012-02-01 | 生化学工業株式会社 | 糖オキサゾリン誘導体の製造方法 |
| CA2454342A1 (en) | 2001-07-24 | 2003-02-06 | Yale University | Methods, compositions and kits relating to chitinases and chitinase-like molecules and inflammatory disease |
| WO2004103368A1 (en) | 2003-05-22 | 2004-12-02 | The Hospital For Sick Children | Treatment of tay sachs or sandhoff diseases by enhancing hexosaminidase activity |
| CN1548053A (zh) | 2003-05-23 | 2004-11-24 | 华晶基因技术有限公司 | 黄芩甙作为治疗焦虑症的药物的新用途 |
| WO2005026156A1 (en) | 2003-09-16 | 2005-03-24 | Astrazeneca Ab | Quinazoline derivatives |
| JP2007518814A (ja) | 2004-01-20 | 2007-07-12 | ザ・スクリップス・リサーチ・インスティテュート | グリコシダーゼ阻害剤によるほ乳類での変性軟骨症の治療 |
| WO2006016904A2 (en) | 2004-04-14 | 2006-02-16 | Uab Research Foundation | Activators of hexosamine biosynthesis as inhibitors of injury induced by ischemia or hemorrhagic shock |
| TW200602314A (en) | 2004-05-28 | 2006-01-16 | Tanabe Seiyaku Co | A novel pyrrolidine compound and a process for preparing the same |
| WO2006008194A1 (en) | 2004-07-23 | 2006-01-26 | Bayer Cropscience Sa | 3-pyridinylethylcarboxamide derivatives as fungicides |
| WO2006031852A1 (en) | 2004-09-13 | 2006-03-23 | Amgen Inc. | Vanilloid receptor ligands and their use in treatments |
| WO2006037069A1 (en) | 2004-09-28 | 2006-04-06 | Allergan, Inc. | Compositions comprising nb-dnj, ne-dnj or d-glucaro-delta-lactam and their uses for the treatment of pain and other neurological conditions |
| AU2006220187B2 (en) * | 2005-03-01 | 2012-11-08 | Simon Fraser University | Selective glycosidase inhibitors, methods of making inhibitors, and uses thereof |
| AT502145B1 (de) | 2005-03-24 | 2012-01-15 | Univ Graz Tech | Glycosidase-hemmendes iminoalditol |
| US7820699B2 (en) | 2005-04-27 | 2010-10-26 | Hoffmann-La Roche Inc. | Cyclic amines |
| AR057982A1 (es) | 2005-10-26 | 2008-01-09 | Boehringer Ingelheim Int | Compuestos de [hetero) arilo con actividad antagonista de mch y composicion farmaceutica que comprende estos compuestos |
| US7919521B2 (en) | 2005-12-05 | 2011-04-05 | Academia Sinica | Five-membered iminocyclitol derivatives as selective and potent glycosidase inhibitors: new structures for antivirals and osteoarthritis therapeutics |
| CN101595111A (zh) | 2006-08-31 | 2009-12-02 | 西蒙·弗雷瑟大学 | 选择性糖苷酶抑制剂及其用途 |
| EP2057171A4 (en) * | 2006-08-31 | 2010-04-21 | Univ Fraser Simon | SELECTIVE GLYCOSIDASE INHIBITORS AND APPLICATIONS THEREOF |
| US8258307B2 (en) | 2006-11-07 | 2012-09-04 | University Of Tokyo | Amide compound or salt thereof, and biofilm inhibitor, biofilm remover and disinfectant containing the same |
| JP5687194B2 (ja) | 2008-08-01 | 2015-03-18 | サイモン フレイザー ユニバーシティ | 選択的グリコシダーゼインヒビターおよびその使用 |
| WO2010012106A1 (en) | 2008-08-01 | 2010-02-04 | Simon Fraser University | Selective glycosidase inhibitors and uses thereof |
| US20110195929A1 (en) | 2008-08-05 | 2011-08-11 | Summit Corporation Plc | Compounds for the treatment of flaviviral infections |
| US20110237538A1 (en) | 2008-08-06 | 2011-09-29 | Summit Corporation Plc | Treatment of lysosomal storage disorders and other proteostatic diseases |
| JP2012502884A (ja) | 2008-09-16 | 2012-02-02 | サイモン フレイザー ユニバーシティ | 選択的グリコシダーゼ阻害剤およびその使用 |
| WO2010049678A2 (en) | 2008-10-31 | 2010-05-06 | Summit Corporation Plc | Treatment of energy utilization diseases |
| AT507745B1 (de) | 2008-12-16 | 2012-01-15 | Forschungsholding Tu Graz Gmbh | Fluorophile glykosidasehemmer |
| WO2011060397A1 (en) | 2009-11-16 | 2011-05-19 | Schering Corporation | Substituted amino heterocycles useful as hiv antagonists |
| US9120781B2 (en) | 2010-05-11 | 2015-09-01 | Simon Fraser University | Selective glycosidase inhibitors and uses thereof |
| TW201249848A (en) | 2010-11-08 | 2012-12-16 | Merck Sharp & Dohme | Selective glycosidase inhibitors and uses thereof |
| WO2012061971A1 (en) | 2010-11-08 | 2012-05-18 | Alectos Therapeutics Inc. | Selective glycosidase inhibitors and uses thereof |
| WO2012061927A1 (en) | 2010-11-08 | 2012-05-18 | Alectos Therapeutics, Inc. | Selective glycosidase inhibitors and uses thereof |
| US8901087B2 (en) | 2010-11-08 | 2014-12-02 | Merck Sharp & Dohme Corp. | Selective glycosidase inhibitors and uses thereof |
| WO2012061972A1 (en) | 2010-11-08 | 2012-05-18 | Alectos Therapeutics Inc. | Selective glycosidase inhibitors and uses thereof |
| BR112013016179A2 (pt) * | 2010-12-23 | 2018-07-10 | Alectos Therapeutics Inc | inibidores seletivos da glicosidase e usos dos mesmos. |
| GB201103526D0 (en) | 2011-03-02 | 2011-04-13 | Summit Corp Plc | Selective glycosidase inhibitors and uses thereof |
| AU2012232658B2 (en) | 2011-03-22 | 2016-06-09 | Advinus Therapeutics Limited | Substituted fused tricyclic compounds, compositions and medicinal applications thereof |
| WO2012126091A1 (en) | 2011-03-24 | 2012-09-27 | Alectos Therapeutics Inc. | Selective glycosidase inhibitors and uses thereof |
| US9718854B2 (en) | 2011-03-31 | 2017-08-01 | Alectos Therapeutics Inc. | Selective glycosidase inhibitors and uses thereof |
| WO2012129802A1 (en) | 2011-03-31 | 2012-10-04 | Alectos Therapeutics Inc. | Pyrano[3,2-d]thiazol derivatives and uses as selective glycosidase inhibitors thereof |
| WO2013000086A1 (en) | 2011-06-27 | 2013-01-03 | Alectos Therapeutics Inc. | Selective glycosidase inhibitors and uses thereof |
| MX364602B (es) | 2011-06-27 | 2019-05-02 | Alectos Therapeutics Inc | Inhibidores selectivos de glicosidasa y usos de los mismos. |
| WO2013000085A1 (en) | 2011-06-27 | 2013-01-03 | Alectos Therapeutics Inc. | Selective glycosidase inhibitors and uses thereof |
| EP2744338B1 (en) | 2011-08-18 | 2016-04-27 | Merck Sharp & Dohme Corp. | Selective glycosidase inhibitors and uses thereof |
| US8884023B2 (en) | 2011-08-25 | 2014-11-11 | Merck Patent Gmbh | Pyrano [3,2-D][1,3]thiazole as glycosidase inhibitors |
| CN104395323B (zh) | 2012-05-08 | 2017-08-01 | 默沙东公司 | 可透过性糖苷酶抑制剂及其用途 |
| EP2890675A4 (en) | 2012-08-31 | 2016-01-13 | Alectos Therapeutics Inc | GLYCOSIDASE INHIBITORS AND USES THEREOF |
| EP2890679A4 (en) | 2012-08-31 | 2016-05-04 | Alectos Therapeutics Inc | GLYCOSIDASE INHIBITORS AND USES THEREOF |
| EP2890678A4 (en) | 2012-08-31 | 2016-01-27 | Alectos Therapeutics Inc | GLYCOSIDASE INHIBITORS AND USES THEREOF |
| EP2890676B1 (en) | 2012-08-31 | 2018-12-05 | Alectos Therapeutics Inc. | Glycosidase inhibitors and uses thereof |
| EP2914604A4 (en) | 2012-10-31 | 2016-07-20 | Alectos Therapeutics Inc | GLYCOSIDASE INHIBITORS AND USES THEREOF |
| WO2014100934A1 (en) | 2012-12-24 | 2014-07-03 | Merck Sharp & Dohme Corp. | Glycosidase inhibitors and uses thereof |
-
2011
- 2011-12-21 BR BR112013016179A patent/BR112013016179A2/pt not_active Application Discontinuation
- 2011-12-21 LT LTEP11850773.0T patent/LT2655388T/lt unknown
- 2011-12-21 AU AU2011349021A patent/AU2011349021B2/en not_active Ceased
- 2011-12-21 CN CN201180066766.4A patent/CN103339138B/zh not_active Expired - Fee Related
- 2011-12-21 TW TW100147743A patent/TWI572609B/zh not_active IP Right Cessation
- 2011-12-21 WO PCT/CA2011/001397 patent/WO2012083435A1/en not_active Ceased
- 2011-12-21 JP JP2013544980A patent/JP5861194B2/ja not_active Expired - Fee Related
- 2011-12-21 DK DK11850773.0T patent/DK2655388T3/en active
- 2011-12-21 MX MX2013007434A patent/MX343822B/es active IP Right Grant
- 2011-12-21 NZ NZ612703A patent/NZ612703A/en not_active IP Right Cessation
- 2011-12-21 HU HUE11850773A patent/HUE030624T2/en unknown
- 2011-12-21 PL PL11850773.0T patent/PL2655388T3/pl unknown
- 2011-12-21 HR HRP20161079TT patent/HRP20161079T1/hr unknown
- 2011-12-21 MY MYPI2013002307A patent/MY165728A/en unknown
- 2011-12-21 US US13/997,484 patent/US9243020B2/en not_active Expired - Fee Related
- 2011-12-21 CA CA2822493A patent/CA2822493C/en not_active Expired - Fee Related
- 2011-12-21 PT PT118507730T patent/PT2655388T/pt unknown
- 2011-12-21 ES ES11850773.0T patent/ES2589164T3/es active Active
- 2011-12-21 EP EP11850773.0A patent/EP2655388B1/en active Active
- 2011-12-21 KR KR1020137019485A patent/KR101979036B1/ko not_active Expired - Fee Related
- 2011-12-21 RU RU2013134345A patent/RU2609210C2/ru not_active IP Right Cessation
- 2011-12-22 AR ARP110104876 patent/AR085004A1/es active IP Right Grant
-
2013
- 2013-06-19 IL IL227055A patent/IL227055A/en active IP Right Grant
- 2013-07-22 ZA ZA2013/05531A patent/ZA201305531B/en unknown
- 2013-07-22 CO CO13173187A patent/CO6821931A2/es active IP Right Grant
-
2015
- 2015-11-26 JP JP2015230912A patent/JP6322177B2/ja active Active
- 2015-12-11 US US14/966,221 patent/US9815861B2/en not_active Expired - Fee Related
-
2016
- 2016-09-07 CY CY20161100886T patent/CY1118157T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1124407T1 (el) | Ενωσεις αναστολεα αυτοταξινης | |
| CY1124311T1 (el) | Παρεμποδιστες dna-pk | |
| CY1124928T1 (el) | Αναστολεις πυραζολυλο κινοξαλινο κινασης | |
| CY1121695T1 (el) | Ενωσεις και συνθεσεις ως αναστολεις κινασης c-kit | |
| CY1122247T1 (el) | Αγωγη καρκινων με τη χρηση τροποποιητων ισομορφης κινασης ρι3 | |
| CY1116424T1 (el) | Παραγωγο αδενινης ως αναστολεας ρι3κ | |
| CY1121460T1 (el) | Διαμορφωση του μεταγωγεα σηματος και του ενεργοποιητη εκφρασης της μεταγραφης 3 (stat3) | |
| CY1121299T1 (el) | Υποκατεστημενες τρικυκλικες ενωσεις ως αναστολεις fgfr | |
| MX364602B (es) | Inhibidores selectivos de glicosidasa y usos de los mismos. | |
| MX343822B (es) | Inhibidores selectivos de glucosidasas, y usos de los mismos. | |
| CY1121653T1 (el) | C1-inh συνθεσεις και μεθοδοι για την προληψη και αγωγη διαταραχων συνδεομενων με ανεπαρκεια αναστολεα c1 εστερασης | |
| CR20120202A (es) | Métodos y composiciones para tratar cáncer | |
| MX2014001717A (es) | Composiciones inmunoterapeuticas de levadura-mucina 1 (muc1) y usos de las mismas. | |
| CY1118452T1 (el) | Ενωσεις και συνθεσεις ως αναστολεις πρωτεϊνικης κινασης | |
| BR112017017727A8 (pt) | Heterociclos bicíclicos como inibidores de fgfr4 | |
| EA201171367A1 (ru) | Винилиндазолильные соединения | |
| EA201270100A1 (ru) | Пиримидиноны в качестве ингибиторов pi3k | |
| EA202090516A3 (ru) | Бициклические гетероциклы в качестве ингибиторов fgfr | |
| TN2013000348A1 (en) | Compounds and compositions as trk inhibitors | |
| EP4116293A3 (en) | Rho kinase inhibitors | |
| CY1125150T1 (el) | Ενωσεις φαινυλο-2-υδροξυ-ακετυλαμινο-2-μεθυλο-φαινυλιου | |
| CY1112077T1 (el) | Θεραπεια με πιρφενιδονη αποφευγοντας την φλουβοξαμινη | |
| MX343534B (es) | Inhibidores de arginasa y sus aplicaciones terapeuticas. | |
| CY1120597T1 (el) | Νεα χρηση | |
| EA200971068A1 (ru) | Триазолиламинопиримидиновые соединения |